Figure 1: Coronal maximum intensity projection fluorine 18 fluoro-2-deoxy-d-glucose (FDG)
PET scan in 72-year-old man being treated with nivolumab for metastatic squamous cell …

To the Editor: It is with great enthusiasm that we present the first reported case of nivolumab-
induced granulomatous inflammation of the pleura diagnosed by medical thoracoscopy. A …

Immune checkpoint inhibitor-induced sarcoid-like reactions and tertiary lymphoid structures
(TLSs) are increasingly recognized but rarely reported in the same patient. We report a …

Eighteen months following nivolumab initiation, restaging scans demonstrated a robust
radiological and metabolic response in the primary tumour, and complete radiological and …

Discussion: Hepatotoxicity is a rare complication seen in ICI therapy. Nivolumab, a PD-1
inhibitor, is associated with a 3% incidence of LFT elevations in hepatocellular and/or …

1. Zambrano E, Reyes-Mugica M, Franchi A, Rosai J. An osteoclast-rich tumor of the
gastrointestinal tract with features resembling clear cell sarcoma of soft parts: reports of 6 …

Immune checkpoint inhibitors represent the newest treatment for stage IV melanoma. These
agents are generally well tolerated, however severe immune-related adverse effects have …

Recent emergence of immune checkpoint inhibitors (ICIs) has revolutionized the treatment
of cancers and produced prolonged response by boosting the immune system against tumor …

Background Sarcoid-like reaction (SLR) is a histological pattern of granulomatous
inflammation that is clinically differentiated from sarcoidosis. Since SLR is known to occur in …

Immune checkpoint inhibitor is a verified standard of care as a second-line chemotherapy for
non-small cell lung cancer. Management of immune-related adverse effects (irAEs) is crucial …